Press Releases

Press Releases

DateTitle 
Mar 07, 2019
BURLINGAME, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and
Mar 05, 2019
BURLINGAME, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will present at the Cowen and
Feb 06, 2019
BURLINGAME, Calif. , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the presentation of updated biomarker and
Jan 30, 2019
BURLINGAME, Calif. , Jan. 30, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present updated data from its lead
Jan 28, 2019
BURLINGAME, Calif. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the appointment of Linda S.
Jan 10, 2019
Company on track to submit Investigational New Drug application for CPI-818 in early 2019 BURLINGAME, Calif. , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely
Jan 08, 2019
Both CPI-006 monotherapy and CPI-006 in combination with CPI-444 trial arms  now enrolling patients at U.S. sites CPI-006 in combination with CPI-444 targets multiple points in the adenosine pathway BURLINGAME, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.